A

Attovia Therapeutics

Attovia Therapeutics is a clinical-stage biopharmaceutical company focused on developing next-generation therapies for immune-mediated diseases. The company holds an exclusive global license to the ATTOBODY biologics platform, which enables the rapid generation of diverse candidate molecules. Attovia has already nominated three product candidates and aims to advance their clinical development with proceeds from their recent IPO.

Total raised
$289M
tracked to date
Latest round
IPO
Aug 6, 2026
Known investors
2
led by Goldman Sachs

Is this your company?

Claim this profile to get matched with investors who fund Health startups in United States.

Claim this profile →

🏆 Featured in Datapile’s Q3 2026 USA Funding Report

Read the Q3 2026 USA report →
Add this badge to your site
<a href="https://datapile.co/reports/q3-2026-usa-startup-funding" target="_blank" rel="noopener" style="display:inline-flex;align-items:center;gap:8px;padding:9px 16px;border-radius:9999px;background:#0B1224;color:#ffffff;font:600 13px/1.2 -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Arial,sans-serif;text-decoration:none;border:1px solid #7C5CFF"><span style="display:inline-block;width:11px;height:11px;border-radius:3px;background:#7C5CFF"></span>Featured in Datapile&rsquo;s Q3 2026 USA Funding Report</a>

Funding history

  1. 1
    $289MIPOAug 6, 2026

    Led by Goldman Sachs

    Announcement ↗

Investors in Attovia Therapeutics

Backers from this company's tracked funding rounds.

Attovia Therapeutics in the news

Coverage of this company's funding, tracked by Datapile.

More Health companies

Recently funded startups in the same category.

Related on Datapile